Work

A phase I study of cabozantinib plus nivolumab (CaboNivo) in patients (pts) refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors

Year: 2016

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdw373.02

Authors: A.B. Apolo, A. Mortazavi, M. Stein, S.K. Pal, N. Davarpanah, H.L. Parnes, Y.M. Ning, D.C. Francis, L.M. Cordes, M. Berniger, S.M. Steinberg, P. Monk, T. Lancaster, T. Mayer, R. Costello, D.P. Bottaro, W.L. Dahut

Institutions: National Cancer Institute, Center for Cancer Research, The Ohio State University Wexner Medical Center, The Ohio State University, Rutgers Cancer Institute, City Of Hope National Medical Center, City of Hope

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2586401019

FWCI: 3.665

Cites:

Cited by: 13

Related to: 10